GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31

Generate Biomedicines, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$12.56+0.47 (+3.89%)

Close on Oct 19, 2026

Market cap: $1.61B
P/E (TTM): –
Dividend yield: –

Generate Biomedicines, Inc. balance sheet

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31
Cash & Equivalents	122	–
Short-Term Investments	100	–
Cash & Short-Term Investments	221	–
Prepaid Expenses & Other	13	–
Total Current Assets	234	–
Property, Plant & Equipment	29	–
Gross Property, Plant & Equipment	77	–
Accumulated Depreciation	-48	–
Operating Lease Right-of-Use Assets	60	–
Other Long-Term Assets	6.81	–
Total Assets	330	–
Accounts Payable	3.84	–
Current Portion of Leases	11	–
Deferred Revenue (Current)	21	–
Other Current Liabilities	2.63	–
Total Current Liabilities	82	–
Long-Term Leases	51	–
Operating Lease Liabilities	61	–
Other Long-Term Liabilities	0.12	–
Total Liabilities	142	–
Common Stock	0.03	–
Additional Paid-In Capital	60	–
Retained Earnings	-676	–
Comprehensive Income & Other	0.11	–
Shareholders' Equity	-616	-435
Noncontrolling Interest	-7.23	–
Total Equity	-616	-435
Total Liabilities & Equity	330	–
Shares Outstanding(shares)	33	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 8.30
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 239.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 3.53
Dividend yield: –